{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T21:11:42Z","timestamp":1789074702626,"version":"build-2803163510"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002920","name":"University Grants Committee Research Grants Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002920","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","primary-care-diabetes.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Primary Care Diabetes"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.pcd.2026.08.005","type":"journal-article","created":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T03:56:51Z","timestamp":1788580611000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Use of fixed-ratio combination of basal insulin and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in Asians with type 2 diabetes"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8927-6764","authenticated-orcid":false,"given":"Alice Pik-Shan","family":"Kong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Kwan","family":"O","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siran","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Yuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana Chung-Ngor","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pcd.2026.08.005_bib1","series-title":"IDF Diabetes Atlas","author":"International Diabetes Federation","year":"2025"},{"issue":"9","key":"10.1016\/j.pcd.2026.08.005_bib2","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nrendo.2013.102","article-title":"Diabetes and its comorbidities-where East meets West","volume":"9","author":"Kong","year":"2013","journal-title":"Nat. Rev. Endocrinol."},{"issue":"1","key":"10.1016\/j.pcd.2026.08.005_bib3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2337\/dci23-0068","article-title":"Diabetes in South Asians: uncovering novel risk factors with longitudinal epidemiologic data: Kelly West Award Lecture 2023","volume":"47","author":"Kanaya","year":"2024","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.pcd.2026.08.005_bib4","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2337\/dci24-0046","article-title":"Lessons learned from epidemiology of type 2 diabetes in South Asians: Kelly West Award Lecture 2024","volume":"48","author":"Mohan","year":"2025","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.pcd.2026.08.005_bib5","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.2337\/diacare.21.12.2191","article-title":"Correct homeostasis model assessment (HOMA) evaluation uses the computer program","volume":"21","author":"Levy","year":"1998","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.pcd.2026.08.005_bib6","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S2213-8587(18)30051-2","article-title":"Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables","volume":"6","author":"Ahlqvist","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"1","key":"10.1016\/j.pcd.2026.08.005_bib7","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2020-001506","article-title":"Novel subgroups of type 2 diabetes and their association with microvascular outcomes in an Asian Indian population: a data-driven cluster analysis: the INSPIRED study","volume":"8","author":"Anjana","year":"2020","journal-title":"BMJ Open. Diabetes Res. Care"},{"issue":"7","key":"10.1016\/j.pcd.2026.08.005_bib8","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.metabol.2004.02.012","article-title":"Insulin secretion and insulin sensitivity at different stages of glucose tolerance: a cross-sectional study of Japanese type 2 diabetes","volume":"53","author":"Fukushima","year":"2004","journal-title":"Metab. Clin. Exp."},{"issue":"6","key":"10.1016\/j.pcd.2026.08.005_bib9","doi-asserted-by":"crossref","first-page":"975","DOI":"10.2337\/diabetes.49.6.975","article-title":"Insulin secretion and insulin sensitivity in relation to glucose tolerance: lessons from the Botnia Study","volume":"49","author":"Tripathy","year":"2000","journal-title":"Diabetes"},{"issue":"6","key":"10.1016\/j.pcd.2026.08.005_bib10","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1007\/s11892-015-0602-9","article-title":"\u03b2 cell dysfunction versus insulin resistance in the pathogenesis of type 2 diabetes in East Asians","volume":"15","author":"Yabe","year":"2015","journal-title":"Curr. Diab Rep."},{"issue":"5","key":"10.1016\/j.pcd.2026.08.005_bib11","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1053\/meta.2001.22558","article-title":"Insulin secretory dysfunction and insulin resistance in the pathogenesis of korean type 2 diabetes mellitus","volume":"50","author":"Kim","year":"2001","journal-title":"Metab. Clin. Exp."},{"issue":"3","key":"10.1016\/j.pcd.2026.08.005_bib12","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3904\/kjim.2000.15.3.211","article-title":"New ADA criteria in the Korean population: fasting blood glucose is not enough for diagnosis of mild diabetes especially in the elderly","volume":"15","author":"Choi","year":"2000","journal-title":"Korean J. Intern. Med."},{"issue":"2","key":"10.1016\/j.pcd.2026.08.005_bib13","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/dmrr.922","article-title":"Early insulin secretion failure leads to diabetes in Chinese subjects with impaired glucose regulation","volume":"25","author":"Qian","year":"2009","journal-title":"Diabetes Metab. Res. Rev."},{"issue":"21","key":"10.1016\/j.pcd.2026.08.005_bib14","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1097\/00029330-200811010-00002","article-title":"Relationship between the level of fasting plasma glucose and beta cell functions in Chinese with or without diabetes","volume":"121","author":"Pang","year":"2008","journal-title":"Chin. Med. J. (Engl. )"},{"issue":"9","key":"10.1016\/j.pcd.2026.08.005_bib15","doi-asserted-by":"crossref","first-page":"2772","DOI":"10.2337\/dc12-2290","article-title":"Evidence of reduced \u03b2-cell function in Asian Indians with mild dysglycemia","volume":"36","author":"Staimez","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pcd.2026.08.005_bib16","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/S0168-8227(98)00038-2","article-title":"Assessing the potential for alpha-glucosidase inhibitors in prediabetic states","volume":"40","author":"Holman","year":"1998","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"6","key":"10.1016\/j.pcd.2026.08.005_bib17","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc12-0413","article-title":"Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"35","author":"Inzucchi","year":"2012","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.pcd.2026.08.005_bib18","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jdiacomp.2011.11.005","article-title":"Trends of insulin use among US adults with type 2 diabetes: the Behavioral Risk Factor Surveillance System, 1995-2007","volume":"26","author":"Li","year":"2012","journal-title":"J. Diabetes Complicat."},{"issue":"4","key":"10.1016\/j.pcd.2026.08.005_bib19","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/dom.13950","article-title":"Real-world data reveal unmet clinical needs in insulin treatment in Asian people with type 2 diabetes: the Joint Asia Diabetes Evaluation (JADE) Register","volume":"22","author":"Kong","year":"2020","journal-title":"Diabetes Obes. Metab."},{"issue":"7","key":"10.1016\/j.pcd.2026.08.005_bib20","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.amjmed.2014.03.018","article-title":"Premature mortality and comorbidities in young-onset diabetes: a 7-year prospective analysis","volume":"127","author":"Chan","year":"2014","journal-title":"Am. J. Med."},{"key":"10.1016\/j.pcd.2026.08.005_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2023.110954","article-title":"Comparison of beta-cell function between Hong Kong Chinese with young-onset type 2 diabetes and late-onset type 2 diabetes","volume":"205","author":"Fan","year":"2023","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"4","key":"10.1016\/j.pcd.2026.08.005_bib22","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.2337\/dc13-2507","article-title":"Severe hypoglycemia identifies vulnerable patients with type 2 diabetes at risk for premature death and all-site cancer: the Hong Kong diabetes registry","volume":"37","author":"Kong","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pcd.2026.08.005_bib23","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1472-6823-14-48","article-title":"Hypoglycaemia, chronic kidney disease and death in type 2 diabetes: the Hong Kong diabetes registry","volume":"14","author":"Kong","year":"2014","journal-title":"BMC Endocr. Disord."},{"issue":"10","key":"10.1016\/j.pcd.2026.08.005_bib24","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s11892-015-0646-x","article-title":"Hypoglycemia and Comorbidities in Type 2 Diabetes","volume":"15","author":"Kong","year":"2015","journal-title":"Curr. Diab Rep."},{"issue":"12","key":"10.1016\/j.pcd.2026.08.005_bib25","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/S2213-8587(14)70137-8","article-title":"Metabolic profiles and treatment gaps in young-onset type 2 diabetes in Asia (the JADE programme): a cross-sectional study of a prospective cohort","volume":"2","author":"Yeung","year":"2014","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"1","key":"10.1016\/j.pcd.2026.08.005_bib26","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00125-004-1599-9","article-title":"An alarmingly high prevalence of diabetic nephropathy in Asian type 2 diabetic patients: the MicroAlbuminuria Prevalence (MAP) Study","volume":"48","author":"Wu","year":"2005","journal-title":"Diabetologia"},{"key":"10.1016\/j.pcd.2026.08.005_bib27","doi-asserted-by":"crossref","DOI":"10.1007\/s00125-021-05494-4","article-title":"Young age at diabetes diagnosis amplifies the effect of diabetes duration on risk of chronic kidney disease: a prospective cohort study","author":"Wu","year":"2021","journal-title":"Diabetologia"},{"issue":"ement_1","key":"10.1016\/j.pcd.2026.08.005_bib28","article-title":"9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes\u20142025","volume":"48","year":"2024","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.pcd.2026.08.005_bib29","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/S2213-8587(24)00157-8","article-title":"Understanding the cause of type 2 diabetes","volume":"12","author":"Taylor","year":"2024","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"5","key":"10.1016\/j.pcd.2026.08.005_bib30","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/s43587-022-00212-0","article-title":"What is an optimal BMI after eighty?","volume":"2","author":"Woo","year":"2022","journal-title":"Nat. Aging"},{"issue":"4","key":"10.1016\/j.pcd.2026.08.005_bib31","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1007\/s12325-020-01614-5","article-title":"Translating iGlarLixi Evidence for the Management of Frequent Clinical Scenarios in Type 2 Diabetes","volume":"38","author":"Skolnik","year":"2021","journal-title":"Adv. Ther."},{"issue":"5","key":"10.1016\/j.pcd.2026.08.005_bib32","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1177\/2042018814556099","article-title":"Basal insulin combined incretin mimetic therapy with glucagon-like protein 1 receptor agonists as an upcoming option in the treatment of type 2 diabetes: a practical guide to decision making","volume":"5","author":"Scholz","year":"2014","journal-title":"Ther. Adv. Endocrinol. Metab."},{"issue":"7(7","key":"10.1016\/j.pcd.2026.08.005_bib33","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/dom.16593","article-title":"What is the 'real-world' experience with fixed-ratio combination therapy (insulin + GLP-1 receptor agonist) in routine clinical practice? Take-home messages for clinicians regarding key outcomes","volume":"27","author":"Frias","year":"2025","journal-title":"Diabetes Obes. Metab."},{"issue":"11","key":"10.1016\/j.pcd.2026.08.005_bib34","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1007\/s13300-024-01645-z","article-title":"Quality of Life in Japanese People with Type 2 Diabetes Switching from Multiple Daily Insulin Injections to Once-Daily iGlarLixi: SIMPLIFY Japan","volume":"15","author":"Ishii","year":"2024","journal-title":"Diabetes Ther."},{"issue":"2","key":"10.1016\/j.pcd.2026.08.005_bib35","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/jebm.12620","article-title":"Comparation of fixed-ratio (IDegLira and iGlarLixi) versus free combination of basal insulin and glucagon-like peptide-1 receptor agonist for uncontrolled type 2 diabetes: A systematic review and network meta-analysis","volume":"17","author":"Weng","year":"2024","journal-title":"J. Evid. Based Med."},{"issue":"1","key":"10.1016\/j.pcd.2026.08.005_bib36","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/dom.14202","article-title":"Gastrointestinal adverse events with insulin glargine\/lixisenatide fixed-ratio combination versus glucagon-like peptide-1 receptor agonists in people with type 2 diabetes mellitus: A network meta-analysis","volume":"23","author":"Rayner","year":"2021","journal-title":"Diabetes Obes. Metab."},{"issue":"4","key":"10.1016\/j.pcd.2026.08.005_bib37","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa1203858","article-title":"Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia","volume":"367","author":"The ORIGIN Trial investigators","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"23","key":"10.1016\/j.pcd.2026.08.005_bib38","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.pcd.2026.08.005_bib39","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S2213-8587(18)30268-7","article-title":"Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial","volume":"6","author":"Muskiet","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"3","key":"10.1016\/j.pcd.2026.08.005_bib40","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-068057","article-title":"Registry randomised trials: a methodological perspective","volume":"13","author":"Doherty","year":"2023","journal-title":"BMJ Open."},{"issue":"3","key":"10.1016\/j.pcd.2026.08.005_bib41","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.3862","article-title":"Effect of a Web-Based Management Guide on Risk Factors in Patients With Type 2 Diabetes and Diabetic Kidney Disease: A JADE Randomized Clinical Trial","volume":"5","author":"Chan","year":"2022","journal-title":"JAMA Netw. Open."},{"issue":"4","key":"10.1016\/j.pcd.2026.08.005_bib42","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.jcjd.2023.03.002","article-title":"Comparison of Efficacy and Safety of Commercially Available Fixed-Ratio Combinations of Insulin Degludec\/Liraglutide and Insulin Glargine\/Lixisenatide: A Network Meta-analysis","volume":"47","author":"Visolyi","year":"2023","journal-title":"Can. J. Diabetes"},{"issue":"1","key":"10.1016\/j.pcd.2026.08.005_bib43","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12902-023-01282-w","article-title":"Direct comparison two fixed-ratio combination glucagon-like peptide receptor agonist and basal insulin on glycemic and non glycemic parameters in type 2 diabetes","volume":"23","author":"Risovic","year":"2023","journal-title":"BMC Endocr. Disord."},{"issue":"8","key":"10.1016\/j.pcd.2026.08.005_bib44","first-page":"2782","article-title":"Comparative efficacy and safety of two fixed ratio combinations in type 2 diabetes mellitus patients previously poorly controlled on different insulin regimens: a multi-centric observational study","volume":"26","author":"Bilic-Curcic","year":"2022","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"issue":"5","key":"10.1016\/j.pcd.2026.08.005_bib45","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/jdi.14151","article-title":"Comparison of efficacy and safety of insulin degludec\/liraglutide and insulin glargine U-100\/lixisenatide in individuals with type 2 diabetes mellitus using professional continuous glucose monitoring","volume":"15","author":"Kawaguchi","year":"2024","journal-title":"J. Diabetes Investig."},{"issue":"2","key":"10.1016\/j.pcd.2026.08.005_bib46","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/dom.14579","article-title":"Cardiovascular and microvascular outcomes with iGlarLixi versus iDegLira: A real-world, population-based cohort study","volume":"24","author":"Cowart","year":"2022","journal-title":"Diabetes Obes. Metab."},{"issue":"8","key":"10.1016\/j.pcd.2026.08.005_bib47","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1056\/NEJMoa1615692","article-title":"Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes","volume":"377","author":"Marso","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.pcd.2026.08.005_bib48","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.pcd.2026.08.005_bib49","doi-asserted-by":"crossref","first-page":"222","DOI":"10.2337\/dc14-2883","article-title":"Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical Trial","volume":"39","author":"Davies","year":"2016","journal-title":"Diabetes Care"},{"issue":"13","key":"10.1016\/j.pcd.2026.08.005_bib50","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1161\/CIRCULATIONAHA.123.066604","article-title":"Cardiovascular Outcomes in GRADE (Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness Study)","volume":"149","author":"Green","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.pcd.2026.08.005_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102181","article-title":"Glucometabolic outcomes of GLP-1 receptor agonist-based therapies in patients with type 2 diabetes: a systematic review and network meta-analysis","volume":"64","author":"Caruso","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"4","key":"10.1016\/j.pcd.2026.08.005_bib52","first-page":"874","article-title":"Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes","volume":"27","author":"Chan","year":"2004","journal-title":"Asian Perspect. RENAAL Study Diabetes Care"},{"issue":"8","key":"10.1016\/j.pcd.2026.08.005_bib53","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1111\/dom.14722","article-title":"Efficacy and safety benefits of iGlarLixi versus insulin glargine 100\u2009U\/mL or lixisenatide in Asian Pacific people with suboptimally controlled type 2 diabetes on oral agents: The LixiLan-O-AP randomized controlled trial","volume":"24","author":"Yang","year":"2022","journal-title":"Diabetes Obes. Metab."},{"issue":"6","key":"10.1016\/j.pcd.2026.08.005_bib54","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.2337\/dc19-2452","article-title":"Efficacy and Safety of 1:1 Fixed-Ratio Combination of Insulin Glargine and Lixisenatide Versus Lixisenatide in Japanese Patients With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs: The LixiLan JP-O1 Randomized Clinical Trial","volume":"43","author":"Watada","year":"2020","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.pcd.2026.08.005_bib55","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1111\/dom.14803","volume":"24","author":"Yuan","year":"2022","journal-title":"Diabetes Obes. Metab."},{"issue":"4","key":"10.1016\/j.pcd.2026.08.005_bib56","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/dom.14005","article-title":"Efficacy and safety of insulin glargine\/lixisenatide fixed-ratio combination (iGlarLixi) in Japanese patients with type 2 diabetes mellitus inadequately controlled on basal insulin and oral antidiabetic drugs: The LixiLan JP-L randomized clinical trial","volume":"22","author":"Kaneto","year":"2020","journal-title":"Diabetes Obes. Metab."},{"issue":"9","key":"10.1016\/j.pcd.2026.08.005_bib57","doi-asserted-by":"crossref","first-page":"3791","DOI":"10.1111\/dom.15724","article-title":"The efficacy and safety of iGlarLixi versus IDegAsp in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli-D randomized controlled trial","volume":"26","author":"Liu","year":"2024","journal-title":"Diabetes Obes. Metab."},{"issue":"12","key":"10.1016\/j.pcd.2026.08.005_bib58","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1111\/dom.14537","article-title":"Benefit of insulin glargine\/lixisenatide for reducing residual hyperglycaemia in Japan: Post hoc analysis of the LixiLan JP-O2 trial","volume":"23","author":"Iizuka","year":"2021","journal-title":"Diabetes Obes. Metab."},{"issue":"5","key":"10.1016\/j.pcd.2026.08.005_bib59","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1111\/dom.16251","article-title":"Treatment satisfaction and time in range after 16\u2009weeks of treatment with iGlarLixi in insulin-naive adults with suboptimally controlled type 2 diabetes","volume":"27","author":"Shah","year":"2025","journal-title":"Diabetes Obes. Metab."},{"issue":"2","key":"10.1016\/j.pcd.2026.08.005_bib60","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/dom.16075","article-title":"Treatment persistence, adherence and healthcare resource utilisation for iGlarLixi versus basal-bolus insulin or premixed insulin in older adult ethnic minorities with type 2 diabetes: SoliEthnicity study","volume":"27","author":"Umpierrez","year":"2025","journal-title":"Diabetes Obes. Metab."},{"issue":"12","key":"10.1016\/j.pcd.2026.08.005_bib61","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1111\/dom.14822","article-title":"Improved patient-reported outcomes with iGlarLixi versus premix BIAsp 30 in people with type 2 diabetes in the SoliMix trial","volume":"24","author":"Polonsky","year":"2022","journal-title":"Diabetes Obes. Metab."},{"issue":"1 Suppl 1","key":"10.1016\/j.pcd.2026.08.005_bib62","first-page":"S266","article-title":"13. Older Adults: Standards of Care in Diabetes-2025","volume":"48","year":"2025","journal-title":"Diabetes Care"}],"container-title":["Primary Care Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1751991826001531?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1751991826001531?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T20:41:28Z","timestamp":1789072888000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1751991826001531"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":62,"alternative-id":["S1751991826001531"],"URL":"https:\/\/doi.org\/10.1016\/j.pcd.2026.08.005","relation":{},"ISSN":["1751-9918"],"issn-type":[{"value":"1751-9918","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of fixed-ratio combination of basal insulin and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in Asians with type 2 diabetes","name":"articletitle","label":"Article Title"},{"value":"Primary Care Diabetes","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcd.2026.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Primary Care Diabetes Europe. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}